On February 2, 2023, ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced the pricing of an underwritten offering of 12 m ADCT shares owned by an affiliate of Auven Therapeutics, at a price of USD 5.00 per share. ADCT itself did not sell any shares in the offering.

The Homburger team was led by Daniel Häusermann (Corporate / M&A, Capital Markets) and included Estelle Piccard (Corporate / M&A, Capital Markets).

Contact

Nanding Susso / Marketing / [email protected]